Navigation Links
HeartWare International Reports Third Quarter Revenues of $7.5 Million
Date:11/4/2009

uted share, compared to a $19.8 million net loss, or a loss of $2.61 per basic and diluted share, in the prior year nine-month period. These figures include a $2.2 million (non-cash) charge recorded during the 2009 period associated with a change in the fair value of a derivative instrument embedded in the $20 million loan facility provided by Thoratec Corporation.

Godshall continued, "We are making the necessary investments in our operating infrastructure, staffing and clinical trials so as to lay the foundation for our continued growth."

The balance sheet was strengthened during the third quarter as a result of a $60 million private placement of common stock entered into in mid August 2009. At September 30, 2009 the balance sheet showed $31.4 million in cash and cash equivalents, with the outstanding $30.7 million of the $60 million private placement having been released from escrow to the Company following stockholder approval of the private placement on October 26, 2009.

The Company will host a conference call on Thursday, November 5, 2009 at 8:00 a.m. U.S. Eastern time (being 12:00 a.m. Australian Eastern Daylight Time between November 5 and 6, 2009) to discuss its third quarter results. The call may be accessed by dialing 1-877-407-4018 five minutes prior to the scheduled start time and referencing "HeartWare." For callers outside the United States, dial +1-201-689-8471. Doug Godshall, Chief Executive Officer, President and Executive Director, and David McIntyre, Chief Financial Officer and Chief Operating Officer, will host the conference call.

A live web cast of the call will also be available at the Company's website (www.heartware.com) by selecting "HeartWare Third Quarter and Nine Months Conference Call" under the section titled "Corporate Presentations" on the HOME page. A replay of the conference call will be available through the above weblink immediately f
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Presentation of HeartWare Clinical Results
2. HeartWare International Clinical Trial Shows 90% Survival at 180 Days
3. U.S. FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U.S. Bridge-to-Transplant Clinical Trial
4. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
5. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
6. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
9. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
10. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
11. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on ... their offering. Developed by Novo Nordisk, ... is an important drug for the treatment of ... a fast- acting insulin analog, starts working fast ...
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Ranibizumab Market, 2012-2019" ... ranibizumab was approved by CFDA to treat wet age- ... a product of Novartis, is available in the Chinese ... developed drug for the treatment of wet AMD in ...
(Date:8/28/2015)... PRINCETON, N.J. , Aug. 28, 2015  IP Shakti, ... Prediqtus, LLC. ... "Our new corporate identity signifies our ... the world,s first predictive analytics platform for patent claim validity." ... with the launch of the proprietary AIA Shield™ platform, the ...
Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2Investigation Report on China's Ranibizumab Market, 2012-2019 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2
(Date:8/30/2015)... ... 2015 , ... The law firm of Tomasik Kotin ... recently elected to membership in the American Board of Trial Advocates (ABOTA). ... outstanding professionalism. , ABOTA is an invitation-only, national organization comprised of judges ...
(Date:8/30/2015)... (PRWEB) , ... August 30, 2015 , ... Natural Rest ... beneficial effects as sleep aids and calming remedies, which help to improve mood disorders ... of a great deal of research in the field of regenerative medicine conducted by ...
(Date:8/29/2015)... ... ... Rio Salado College President Chris Bustamante announced on Aug. 19 ... Initiatives and Information Services. O’Shea, who has served Rio Salado for the last two ... through innovative technologies and strategies. , “I am very proud to be able to ...
(Date:8/29/2015)... PA (PRWEB) , ... August 29, 2015 , ... ... due to insufficient scrotal support and protection against dribbled urine and sweat. "In ... from Manhasset Hills, N.Y. , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides ...
(Date:8/29/2015)... , ... August 29, 2015 , ... ProDrop Particles includes ... Each preset contains 15 seconds of unique footage that users can shrink and stretch ... zoom, attract and more. Users can customize color, brightness, scale, speed, range, and flare ...
Breaking Medicine News(10 mins):Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 2Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 3Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2
... THURSDAY, Feb. 23 (HealthDay News) -- Children with ... attention-deficit hyperactivity disorder (ADHD) and other related disorders, but ... Researchers analyzed data from more than 1,000 U.S. teens ... of psychiatric medications in those with autism, ADHD and ...
... Reinberg HealthDay Reporter , THURSDAY, Feb. 23 (HealthDay ... but this winter,s flu season is finally here, say experts ... They report that flu activity picked up in the past ... influenza season since 1987-1988. Lab-confirmed cases of influenza have now ...
... CINCINNATI Scientists have developed a unique compound ... blood cells known to fuel ailments like cancer ... Past attempts to identify new compounds ... molecules in cells have been complicated by toxicity ...
... WEDNESDAY, Feb. 22 (HealthDay News) -- Melanoma that has spread ... but a new drug appears to double survival for those ... A mutation in the BRAF protein occurs in about ... a drug approved by the U.S. Food and Drug Administration ...
... Feb. 23 (HealthDay News) -- The first molecular evidence linking ... death could lead to new methods of diagnosis and therapy ... study suggests. Abnormal heart rhythms called ventricular arrhythmias are ... the primary cause of death from heart disease. Experts have ...
... HealthDay Reporter , THURSDAY, Feb. 23 (HealthDay News) -- ... might just be the beginning of your spring allergies ... had warmer-than-average winter weather, which is causing trees to ... Stanley Fineman, president of the American College of Allergy, ...
Cached Medicine News:Health News:Meds for Autism Not Well Understood: Study 2Health News:Flu Season Off to a Very Late Start: CDC 2Health News:New class of compounds stops disease-fueling inflammation in lab tests 2Health News:New class of compounds stops disease-fueling inflammation in lab tests 3Health News:New Melanoma Drug May Extend Survival 2Health News:New Melanoma Drug May Extend Survival 3Health News:Study Links 'Body Clock' to Sudden Cardiac Death 2Health News:Mild Winter Heralds Early Sneezin' Season 2Health News:Mild Winter Heralds Early Sneezin' Season 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: